Beta
Company data is growing.
← All companies
/
Top lists
/
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
2016–2025 · 469 US lab companies
2026-08-05
Overview
Earnings
Margins
Cash flow
Balance
Capital
Plot
USD millions
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
4 860
5 872
6 711
7 863
8 497
16 072
12 173
13 117
14 202
14 343
Operating profit (EBIT)
1 331
2 080
2 534
2 210
3 577
8 947
4 739
4 047
3 991
3 578
Net income attributable to shareholders
896
1 199
2 444
2 116
3 513
8 075
4 338
3 954
4 413
4 505
EBIT margin
27,4%
35,4%
37,8%
28,1%
42,1%
55,7%
38,9%
30,9%
28,1%
25,0%
Gross margin
—
—
—
94,7%
92,6%
—
93,4%
92,9%
92,3%
92,1%
Operating cash flow
1 473
1 307
2 195
2 430
2 618
7 081
5 015
4 594
4 421
4 979
Free cash flow
961
1 034
1 812
2 000
2 004
6 529
4 425
3 875
3 665
4 081
Cash
535
813
1 468
1 618
2 194
2 886
3 106
2 730
2 488
3 118
0
5 000
10 000
15 000
20 000
0,0%
20,0%
40,0%
60,0%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
4 860
5 872
6 711
7 863
8 497
16 072
12 173
13 117
14 202
14 343
1 331
2 080
2 534
2 210
3 577
8 947
4 739
4 047
3 991
3 578